Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 945-953

  Kang, Hye Jin ^a   Lee, Seung Sook ^a   Byun, Byung Hyun ^a   Kim, Kyeong Min ^b   Lim, Ilhan ^a   Choi, Chang Woon ^a   Suh, Cheolwon ^c   Kim, Won Seog ^d   Nam, Seung Hyun ^e   Lee, Soon Il ^f   Eom, Hyeon Seok ^g   Shin, Dong Yeop ^a   Lim, Sang Moo ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Veterans Health Service Medical Center   (South Korea)

^f Dankook University College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

Author keywords

131I rituximab; B cell NHL; Radioimmunotherapy; Refractory; Relapsed

Indexed keywords

ANTINEOPLASTIC AGENT; IODINE RITUXIMAB I 131; UNCLASSIFIED DRUG; 131I RITUXIMAB; 131I-RITUXIMAB; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REPEATED DRUG DOSE; RETREATMENT; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; MIDDLE AGED; MORTALITY; RECURRENT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RECURRENCE;

MLCS; MLOWN;

EID: 84878858810     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2087-z     Document Type: Article

References (16)

1. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19(19):3918-3928 (Pubitemid 32912019)
2. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20(10):2453-2463 (Pubitemid 34525730)
3. Leahy MF, Seymour JF, Hicks RJ, Turner JH (2006) Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 24(27):4418-4425 (Pubitemid 46646247)
4. Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, Suh C, Yang SH, Lim SM (2011) Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Asia Pac J Clin Oncol 7(2):136-145
5. Stabin MG (1996) MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37(3):538-546 (Pubitemid 26094290)
6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol 17(4):1244
7. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N (2011) Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 9(5):484-560
8. Schaefer NG, Huang P, Buchanan JW, Wahl RL (2011) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med 52(5):830-838
9. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL (2010) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med 51(6):987-994
10. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329(17):1219-1224 (Pubitemid 23306322)
11. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102(7):2351-2357 (Pubitemid 37193569)
12. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'Donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106(8):2896-2902 (Pubitemid 41510771)
13. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ (2002) Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94(4 Suppl):1332-1348 (Pubitemid 34150897)
14. DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, O'Grady LF, Raventos A, Kroger LA, Macey DJ, McGahan JP, Mills SL, Shen S (1998) Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 13(4):239-254 (Pubitemid 28484004)
15. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP (1998) Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16(10):3246-3256 (Pubitemid 28481618)
16. Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL (1995) Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 55(23 Suppl):5916s-5920s